"This amendment to expand our rights to commercialise Covaxin into Canada speaks to our strong relationship with Bharat Biotech and our joint dedication to bring this unique yet traditional vaccine to additional countries. As we work towards the submission of the emergency use application in the US, we will simultaneously seek authorisation under interim order for emergency use in Canada. We believe Covaxin has the potential to play a key role in saving lives from Covid-19 in the US and Canada, as well as across the globe, due to the strong immune response it generates against multiple antigens," Ocugen co-founder, Chairman of Board and CEO, Dr Shankar Musunuri, said. "Covaxin has demonstrated an excellent safety record in human clinical trials and in vaccine administration under emergency use in India. Our goal for all vaccines developed at Bharat Biotech is to provide global access.